CVM
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Peer-reviewed study supported Multikine's biomarker strategy and potential overall survival benefit ahead of its confirmatory registration studyAug 4, 2026
- CEL-SCI launched an FDA registration-enabling Phase 3 confirmatory study for Multikine in newly diagnosed head and neck cancerJul 13, 2026
- CEL-SCI advanced Multikine immunotherapy through a dual U.S. registration study and Saudi market strategyJun 16, 2026
- CEL-SCI signs strategic agreement with Amarox for Multikine registration and commercialization in Saudi ArabiaMay 11, 2026
- CEL-SCI's Multikine head and neck cancer immunotherapy breakthrough medicine designation filed in Saudi Arabia, enabling patient access and reimbursement upon granting in approx. 60 days based on SFDA timelineAug 14, 2025